Sage Rhino Capital LLC Biogen Inc. Transaction History

Sage Rhino Capital LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 04, 2022	SELL	$223.92 - $287.77 $170,179 - $218,705	-760 Closed	0 $0
Q3 2021 Oct 18, 2021	SELL	$282.99 - $369.05 $848 - $1,107	-3 Reduced 0.39%	760 $215,000
Q2 2021 Jul 27, 2021	BUY	$259.0 - $414.71 $3,108 - $4,976	12 Added 1.6%	763 $264,000
Q1 2021 May 04, 2021	BUY	$242.95 - $284.63 $182,455 - $213,757	751 New	751 $210,000
Q4 2020 Feb 03, 2021	SELL	$236.26 - $355.63 $185,227 - $278,813	-784 Closed	0 $0
Q3 2020 Nov 05, 2020	SELL	$264.77 - $305.71 $1,853 - $2,139	-7 Reduced 0.88%	784 $222,000
Q2 2020 Jul 30, 2020	SELL	$258.66 - $342.55 $3,362 - $4,453	-13 Reduced 1.62%	791 $212,000
Q1 2020 Apr 29, 2020	BUY	$268.85 - $341.04 $1,881 - $2,387	7 Added 0.88%	804 $254,000
Q4 2019 Jan 31, 2020	BUY	$220.06 - $304.07 $175,387 - $242,343	797 New	797 $236,000

1,025

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $26.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Sage Rhino Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Sage Rhino Capital LLC with notifications on news.